| scholarly article | Q13442814 |
| P50 | author | Jonathan J Dennis | Q56426771 |
| P2093 | author name string | Karlene H Lynch | |
| P2860 | cites work | Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. | Q44323706 |
| Successful treatment of cepacia syndrome | Q44596011 | ||
| Isolation of Burkholderia cepacia complex genomovars from waters. | Q44687374 | ||
| Polyphasic Taxonomy in the Genus Burkholderia Leading to an Emended Description of the Genus and Proposition of Burkholderia vietnamiensis sp. nov. for N2-Fixing Isolates from Rice in Vietnam | Q45312493 | ||
| Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model | Q46525657 | ||
| Burkholderia cenocepacia phage BcepMu and a family of Mu-like phages encoding potential pathogenesis factors | Q47378921 | ||
| Lysogeny and bacteriophage host range within the Burkholderia cepacia complex | Q47911814 | ||
| Influence of taxonomic status on the in vitro antimicrobial susceptibility of the Burkholderia cepacia complex. | Q48730237 | ||
| Rz/Rz1 lysis gene equivalents in phages of Gram-negative hosts. | Q51701491 | ||
| CRISPR/Cas and Cmr modules, mobility and evolution of adaptive immune systems. | Q52422353 | ||
| Characterization of bacteriophage CP1, an organic solvent sensitive phage associated with Pseudomonas cepacia | Q52704491 | ||
| A new small temperate DNA phage BcP15 isolated from Burkholderia cepacia DR11. | Q53134396 | ||
| The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen, Pseudomonas aeruginosa. | Q53618798 | ||
| Increased frequency of genomic alterations in Staphylococcus aureus during chronic infection is in part due to phage mobilization. | Q53848247 | ||
| Evidence of transmission ofBurkholderia cepacia,Burkholderia multivoransandBurkholderia dolosaamong persons with cystic fibrosis | Q54743699 | ||
| Enacyloxins Are Products of an Unusual Hybrid Modular Polyketide Synthase Encoded by a Cryptic Burkholderia ambifaria Genomic Island | Q57590249 | ||
| Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells | Q59073603 | ||
| The promise of bacteriophage therapy for Burkholderia cepacia complex respiratory infections | Q21131311 | ||
| Classification of Myoviridae bacteriophages using protein sequence similarity | Q21263044 | ||
| The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats | Q21284230 | ||
| A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa ; a preliminary report of efficacy | Q22061813 | ||
| The tRNAscan-SE, snoscan and snoGPS web servers for the detection of tRNAs and snoRNAs | Q24530279 | ||
| The HHpred interactive server for protein homology detection and structure prediction | Q24530456 | ||
| Gapped BLAST and PSI-BLAST: a new generation of protein database search programs | Q24545170 | ||
| GeneMark.hmm: new solutions for gene finding | Q24546288 | ||
| Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei | Q24564168 | ||
| Dispersing biofilms with engineered enzymatic bacteriophage | Q24684087 | ||
| Experimental phage therapy against Staphylococcus aureus in mice | Q24685170 | ||
| CoreGenes: a computational tool for identifying and cataloging "core" genes in a set of small genomes | Q24791169 | ||
| The price of innovation: new estimates of drug development costs | Q28212140 | ||
| Marine cyanophages and light | Q28274187 | ||
| The multifarious, multireplicon Burkholderia cepacia complex | Q28301994 | ||
| Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa | Q28492507 | ||
| Bacteriophages and their genomes | Q28743530 | ||
| Genetically engineered virulent phage banks in the detection and control of emergent pathogenic bacteria | Q28748827 | ||
| CD-Search: protein domain annotations on the fly | Q29615328 | ||
| Evolution and classification of the CRISPR-Cas systems | Q29616645 | ||
| Genetic, biochemical, and clinical features of chronic granulomatous disease. | Q30168989 | ||
| Analysis of high-throughput sequencing and annotation strategies for phage genomes | Q30483489 | ||
| Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates | Q30658029 | ||
| 5500 Phages examined in the electron microscope | Q33260858 | ||
| Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov. and Burkholderia metallica sp. nov., novel species within the Burkholderia cepacia complex | Q33348917 | ||
| Preparation of a phage DNA fragment library for whole genome shotgun sequencing | Q33392951 | ||
| Genomic sequence and activity of KS10, a transposable phage of the Burkholderia cepacia complex | Q33394398 | ||
| Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. | Q33397958 | ||
| Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials | Q33419859 | ||
| Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection | Q33622945 | ||
| Genetic and phenotypic diversity in Burkholderia: contributions by prophage and phage-like elements | Q33643800 | ||
| Genomic analysis and relatedness of P2-like phages of the Burkholderia cepacia complex | Q33727287 | ||
| Serotype-converting bacteriophages and O-antigen modification in Shigella flexneri | Q33818885 | ||
| The complete nucleotide sequence of phi CTX, a cytotoxin-converting phage of Pseudomonas aeruginosa: implications for phage evolution and horizontal gene transfer via bacteriophages | Q33852693 | ||
| Comparative phage genomics and the evolution of Siphoviridae: insights from dairy phages | Q33929777 | ||
| Lysogenic conversion by a filamentous phage encoding cholera toxin | Q34062735 | ||
| The genome sequence of Clostridium botulinum type C neurotoxin-converting phage and the molecular mechanisms of unstable lysogeny | Q34132692 | ||
| The prospect for bacteriophage therapy in Western medicine | Q34201438 | ||
| Divergence and mosaicism among virulent soil phages of the Burkholderia cepacia complex | Q34233220 | ||
| Multidrug-resistant enterococci lack CRISPR-cas | Q34285916 | ||
| Old dogma, new tricks--21st Century phage therapy | Q34287638 | ||
| Conserved translational frameshift in dsDNA bacteriophage tail assembly genes. | Q34356558 | ||
| Phages of dairy bacteria | Q34360779 | ||
| Structural analysis of dispersin B, a biofilm-releasing glycoside hydrolase from the periodontopathogen Actinobacillus actinomycetemcomitans | Q34416551 | ||
| Comparative genomics and evolution of the tailed-bacteriophages. | Q34433982 | ||
| Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. | Q34483463 | ||
| Mucociliary clearance in cystic fibrosis | Q34581003 | ||
| Unifying classical and molecular taxonomic classification: analysis of the Podoviridae using BLASTP-based tools | Q34786602 | ||
| Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. | Q34885744 | ||
| Prevalence, conservation and functional analysis of Yersinia and Escherichia CRISPR regions in clinical Pseudomonas aeruginosa isolates | Q34954589 | ||
| Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved | Q34990712 | ||
| Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. | Q34996099 | ||
| Genomes and characterization of phages Bcep22 and BcepIL02, founders of a novel phage type in Burkholderia cenocepacia | Q35274632 | ||
| Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. | Q35536317 | ||
| Population and evolutionary dynamics of phage therapy | Q35709197 | ||
| Case studies of the spatial heterogeneity of DNA viruses in the cystic fibrosis lung | Q35991304 | ||
| Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada | Q36014916 | ||
| Role of phages in the pathogenesis of Burkholderia, or 'Where are the toxin genes in Burkholderia phages?'. | Q36118037 | ||
| Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review. | Q36533618 | ||
| Comparative genomics and an insect model rapidly identify novel virulence genes of Burkholderia mallei | Q36540498 | ||
| Prediction of lipoprotein signal peptides in Gram-negative bacteria | Q36572165 | ||
| Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center | Q36669829 | ||
| Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. | Q36899142 | ||
| The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients | Q37033480 | ||
| Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage | Q37069059 | ||
| The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage | Q37111067 | ||
| Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy | Q37114251 | ||
| Preventing biofilms of clinically relevant organisms using bacteriophage | Q37375379 | ||
| CRISPR-based adaptive and heritable immunity in prokaryotes | Q37568446 | ||
| Mycobacteriophages: genes and genomes | Q37763219 | ||
| Studying bacterial transcriptomes using RNA-seq | Q37796158 | ||
| Classification and identification of the Burkholderia cepacia complex: Past, present and future | Q37831692 | ||
| Bacteriophages for the treatment of Pseudomonas aeruginosa infections | Q37853657 | ||
| Predicting genes expressed via -1 and +1 frameshifts | Q38516411 | ||
| Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection | Q39374494 | ||
| Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms | Q39491332 | ||
| In vitro lung delivery of bacteriophages KS4-M and ΦKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis | Q39833543 | ||
| Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage | Q40164333 | ||
| Characterization of DC1, a broad-host-range Bcep22-like podovirus | Q40598053 | ||
| Killing of Mycobacterium avium and Mycobacterium tuberculosis by a mycobacteriophage delivered by a nonvirulent mycobacterium: a model for phage therapy of intracellular bacterial pathogens | Q40629899 | ||
| Pseudomonas cepacia infection in cystic fibrosis: an emerging problem | Q40829590 | ||
| Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation | Q40907519 | ||
| Burkholderia cepacia: medical, taxonomic and ecological issues | Q41260421 | ||
| The population biology of bacterial viruses: why be temperate | Q41577540 | ||
| A complete lipopolysaccharide inner core oligosaccharide is required for resistance of Burkholderia cenocepacia to antimicrobial peptides and bacterial survival in vivo. | Q41857195 | ||
| Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing. | Q41913539 | ||
| Experimental bacteriophage therapy increases survival of Galleria mellonella larvae infected with clinically relevant strains of the Burkholderia cepacia complex. | Q42026295 | ||
| Development of a species-specific fur gene-based method for identification of the Burkholderia cepacia complex | Q42083986 | ||
| High-temperature-induced transposition of insertion elements in burkholderia multivorans ATCC 17616 | Q42122691 | ||
| Inactivation of Burkholderia cepacia complex phage KS9 gp41 identifies the phage repressor and generates lytic virions | Q42216737 | ||
| Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis | Q42948700 | ||
| Isolation of Burkholderia cenocepacia and Burkholderia vietnamiensis from human sewage. | Q43368859 | ||
| In vitro activity of ceftazidime, ciprofloxacin, meropenem, minocycline, tobramycin and trimethoprim/sulfamethoxazole against planktonic and sessile Burkholderia cepacia complex bacteria | Q43618599 | ||
| Genetically modified filamentous phage as bactericidal agents: a pilot study | Q43814540 | ||
| N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. | Q43820097 | ||
| Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host | Q44045761 | ||
| P433 | issue | 3 | |
| P921 | main subject | Burkholderia cepacia | Q139227 |
| bacteriophage | Q165028 | ||
| P304 | page(s) | 221-235 | |
| P577 | publication date | 2012-02-17 | |
| P1433 | published in | Canadian Journal of Microbiology | Q15752448 |
| P1476 | title | Cangene gold medal award lecture - Genomic analysis and modification of Burkholderia cepacia complex bacteriophages | |
| P478 | volume | 58 |
| Q38020842 | Bacteriophage based probes for pathogen detection. |
| Q34296269 | Comparative analysis of two phenotypically-similar but genomically-distinct Burkholderia cenocepacia-specific bacteriophages |
| Q34974472 | Genomic characterization of JG068, a novel virulent podovirus active against Burkholderia cenocepacia. |
| Q37313625 | Identification and characterization of ϕH111-1: A novel myovirus with broad activity against clinical isolates of Burkholderia cenocepacia |
| Q28076246 | Modular Approach to Select Bacteriophages Targeting Pseudomonas aeruginosa for Their Application to Children Suffering With Cystic Fibrosis |
Search more.